Plasma proteome in multiple sclerosis disease progression
Abstract Background The pathophysiology of multiple sclerosis disease progression remains undetermined. The aim of this study was to identify differences in plasma proteome during different stages of MS disease progression. Methods We used a multiplex aptamer proteomics platform (Somalogic) for sens...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-09-01
|
| Series: | Annals of Clinical and Translational Neurology |
| Online Access: | https://doi.org/10.1002/acn3.771 |
| _version_ | 1819071540128382976 |
|---|---|
| author | Arjan Malekzadeh Cyra Leurs Wessel vanWieringen Martijn D. Steenwijk Menno M. Schoonheim Michael Amann Yvonne Naegelin Jens Kuhle Joep Killestein Charlotte E. Teunissen |
| author_facet | Arjan Malekzadeh Cyra Leurs Wessel vanWieringen Martijn D. Steenwijk Menno M. Schoonheim Michael Amann Yvonne Naegelin Jens Kuhle Joep Killestein Charlotte E. Teunissen |
| author_sort | Arjan Malekzadeh |
| collection | DOAJ |
| description | Abstract Background The pathophysiology of multiple sclerosis disease progression remains undetermined. The aim of this study was to identify differences in plasma proteome during different stages of MS disease progression. Methods We used a multiplex aptamer proteomics platform (Somalogic) for sensitive detection of 1129 proteins in plasma. MS patients were selected and categorized based on baseline and a 4‐year follow‐up EDSS (delta EDSS) scores; relapse‐onset (RO) slow progression (n = 31), RO with rapid progression (n = 29), primary progressive (n = 30), and healthy controls (n = 20). The relation of baseline plasma protein levels with delta EDSS and different MRI progression parameters were assessed using linear regression models. Results Regression analyses of plasma proteins with delta EDSS showed six significant associations. Strong associations were found for the proteins LGLAS8 (P = 7.64 × 10−5, q = 0.06), CCL3 (P = 0.0001, q = 0.06), and RGMA (P = 0.0005, q = 0.09). In addition, associations of plasma proteins were found with percentage brain volume for C3 (P = 2,08 × 10−9, q = 1,70 × 10−6), FGF9 (P = 3,42 × 10−9, q = 1,70 × 10−6), and EHMT2 (P = 0.0007, q = 0.01). Most of the significant markers were associated with cell‐cell and cell‐extracellular matrix adhesion, immune system communication, immune system activation, and complement pathways. Conclusions Our results revealed eight novel biomarkers related to clinical and radiological progression in MS. These results indicate that changes in immune system, complement pathway and ECM remodeling proteins contribute to MS progression and may therefore be further explored for use in prognosis of MS. |
| first_indexed | 2024-12-21T17:23:27Z |
| format | Article |
| id | doaj.art-2dcba6eb08e94bdeb938fb2fc1264d0b |
| institution | Directory Open Access Journal |
| issn | 2328-9503 |
| language | English |
| last_indexed | 2024-12-21T17:23:27Z |
| publishDate | 2019-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Annals of Clinical and Translational Neurology |
| spelling | doaj.art-2dcba6eb08e94bdeb938fb2fc1264d0b2022-12-21T18:56:07ZengWileyAnnals of Clinical and Translational Neurology2328-95032019-09-01691582159410.1002/acn3.771Plasma proteome in multiple sclerosis disease progressionArjan Malekzadeh0Cyra Leurs1Wessel vanWieringen2Martijn D. Steenwijk3Menno M. Schoonheim4Michael Amann5Yvonne Naegelin6Jens Kuhle7Joep Killestein8Charlotte E. Teunissen9Department of Clinical Chemistry Amsterdam University Medical Centre Amsterdam The NetherlandsDepartment of Neurology Amsterdam University Medical Centre Amsterdam The NetherlandsDepartment of Mathematics Amsterdam University Medical Centre Amsterdam The NetherlandsDepartment of Anatomy and Neurosciences Amsterdam Neuroscience MS Center Amsterdam Amsterdam University Medical Centre Amsterdam The NetherlandsDepartment of Anatomy and Neurosciences Amsterdam Neuroscience MS Center Amsterdam Amsterdam University Medical Centre Amsterdam The NetherlandsDivision of Diagnostic and Interventional Neuroradiology Department of Radiology and Nuclear Medicine University Hospital Basel Basel SwitzerlandDepartment of Biomedicine and Clinical Research University Hospital Basel Basel SwitzerlandDepartment of Biomedicine and Clinical Research University Hospital Basel Basel SwitzerlandDepartment of Neurology Amsterdam University Medical Centre Amsterdam The NetherlandsDepartment of Clinical Chemistry Amsterdam University Medical Centre Amsterdam The NetherlandsAbstract Background The pathophysiology of multiple sclerosis disease progression remains undetermined. The aim of this study was to identify differences in plasma proteome during different stages of MS disease progression. Methods We used a multiplex aptamer proteomics platform (Somalogic) for sensitive detection of 1129 proteins in plasma. MS patients were selected and categorized based on baseline and a 4‐year follow‐up EDSS (delta EDSS) scores; relapse‐onset (RO) slow progression (n = 31), RO with rapid progression (n = 29), primary progressive (n = 30), and healthy controls (n = 20). The relation of baseline plasma protein levels with delta EDSS and different MRI progression parameters were assessed using linear regression models. Results Regression analyses of plasma proteins with delta EDSS showed six significant associations. Strong associations were found for the proteins LGLAS8 (P = 7.64 × 10−5, q = 0.06), CCL3 (P = 0.0001, q = 0.06), and RGMA (P = 0.0005, q = 0.09). In addition, associations of plasma proteins were found with percentage brain volume for C3 (P = 2,08 × 10−9, q = 1,70 × 10−6), FGF9 (P = 3,42 × 10−9, q = 1,70 × 10−6), and EHMT2 (P = 0.0007, q = 0.01). Most of the significant markers were associated with cell‐cell and cell‐extracellular matrix adhesion, immune system communication, immune system activation, and complement pathways. Conclusions Our results revealed eight novel biomarkers related to clinical and radiological progression in MS. These results indicate that changes in immune system, complement pathway and ECM remodeling proteins contribute to MS progression and may therefore be further explored for use in prognosis of MS.https://doi.org/10.1002/acn3.771 |
| spellingShingle | Arjan Malekzadeh Cyra Leurs Wessel vanWieringen Martijn D. Steenwijk Menno M. Schoonheim Michael Amann Yvonne Naegelin Jens Kuhle Joep Killestein Charlotte E. Teunissen Plasma proteome in multiple sclerosis disease progression Annals of Clinical and Translational Neurology |
| title | Plasma proteome in multiple sclerosis disease progression |
| title_full | Plasma proteome in multiple sclerosis disease progression |
| title_fullStr | Plasma proteome in multiple sclerosis disease progression |
| title_full_unstemmed | Plasma proteome in multiple sclerosis disease progression |
| title_short | Plasma proteome in multiple sclerosis disease progression |
| title_sort | plasma proteome in multiple sclerosis disease progression |
| url | https://doi.org/10.1002/acn3.771 |
| work_keys_str_mv | AT arjanmalekzadeh plasmaproteomeinmultiplesclerosisdiseaseprogression AT cyraleurs plasmaproteomeinmultiplesclerosisdiseaseprogression AT wesselvanwieringen plasmaproteomeinmultiplesclerosisdiseaseprogression AT martijndsteenwijk plasmaproteomeinmultiplesclerosisdiseaseprogression AT mennomschoonheim plasmaproteomeinmultiplesclerosisdiseaseprogression AT michaelamann plasmaproteomeinmultiplesclerosisdiseaseprogression AT yvonnenaegelin plasmaproteomeinmultiplesclerosisdiseaseprogression AT jenskuhle plasmaproteomeinmultiplesclerosisdiseaseprogression AT joepkillestein plasmaproteomeinmultiplesclerosisdiseaseprogression AT charlotteeteunissen plasmaproteomeinmultiplesclerosisdiseaseprogression |